Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 71%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

enGene Holdings Inc. demonstrates a positive outlook due to its strong clinical results and regulatory progress, particularly with the RMAT designation for its lead candidate, detalimogene, which positions the company to capture a significant share in the non-muscle invasive bladder cancer market. The company’s strategic advancements have led to a six-month complete response (CR) rate aligned with best-in-class therapies while leveraging the non-viral nature of its delivery platform, enhancing its adoption potential. Additionally, the rise in research and development expenses reflects commitment to pivotal studies, further supported by an upward revision of the discounted cash flow-derived price target, indicating growing confidence in the company's future revenue generation capabilities.

Bears say

enGene Holdings Inc. faces a negative outlook primarily due to disappointing performance in the ongoing LEGEND trial for Detalimogene, coupled with unexpected safety issues that may hinder its development. The changing regulatory landscape for approvals in non-muscle invasive bladder cancer (NMIBC) and the emergence of unforeseen competition add to the company's challenges, particularly as clinical response rates (CR) have fallen below prior expectations. Additionally, higher than anticipated capital requirements may necessitate further equity financing, raising dilution risks for existing shareholders and potentially impacting the company's overall financial health.

ENGN has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 71% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 7 analysts, ENGN has a Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.